Evropska unija - slovenščina - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - dalbavancin hydrochloride - soft tissue infections; skin diseases, bacterial - antibacterials za sistemsko uporabo, - zdravljenje, akutna bakterijska kože in strukturo kožo okužb (absssi) pri odraslih.

Evropska unija - slovenščina - EMA (European Medicines Agency)

advanz pharma limited - obeticholic kisline - ciroza jeter, biliary - terapija z jetri in jeter - ocaliva je indicirano za zdravljenje primarnim holangitisom žolčem (znan tudi kot primarna biliarna ciroza) v kombinaciji z ursodeoxycholic kisline (udca) pri odraslih s nezadosten odziv na udca ali kot monoterapijo pri odraslih ni mogoče prenašati udca.

Evropska unija - slovenščina - EMA (European Medicines Agency)

correvio - vernakalant hidroklorid - atrijska fibrilacija - srčna terapija - hitro pretvorbo nedavni nastop atrijsko fibrilacijo, da sinus ritem pri odraslih:za ne-operaciji bolniki: atrijska fibrilacija .

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

shire pharmaceutical contracts ltd - mesalazin - tableta s podaljšanim sproščanjem - mesalazin 1200 mg / 1 tableta - mesalazin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

shire - mesalazin - tableta s podaljšanim sproščanjem - mesalazin 1200 mg / 1 tableta - mesalazin

Evropska unija - slovenščina - EMA (European Medicines Agency)

advanced accelerator applications - l-arginine hydrochloride, l-lysine hydrochloride - sevanje poškodb - detoxifying agents for antineoplastic treatment - lysakare je označen za zmanjšanje ledvične izpostavljenost sevanju v peptid-receptor radionuklidov terapija (prrt) z lutetium (177lu) oxodotreotide pri odraslih.

Evropska unija - slovenščina - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - trastuzumab deruxtecan - neoplazme dojke - antineoplastična sredstva - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.

Evropska unija - slovenščina - EMA (European Medicines Agency)

pharmaand gmbh - rucaparib camsylate - ovarijske neoplazme - antineoplastična sredstva - rubraca is indicated as monotherapy for the maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. rubraca je označen kot monotherapy za vzdrževanje zdravljenje odraslih bolnikov s platino-občutljive relapsed visoko-kakovostni razred epitelnih jajčnikov, fallopian tube, ali primarni trebušno raka, ki so v odziv (popolna ali delna) platinum, ki temelji kemoterapijo.

Evropska unija - slovenščina - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - doksorubicinijev klorid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastična sredstva - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

Evropska unija - slovenščina - EMA (European Medicines Agency)

advanced accelerator applications - edotreotid - neuroendocrine tumors; radionuclide imaging - diagnostični radiofarmacevtiki - to zdravilo je samo za diagnostično uporabo. po radioaktivnem označevanju z galija (68ga) klorid rešitev, rešitev galija (68ga) edotreotide pridobljen je označen za positron emission tomografija (pet) slikanje somatostatin receptor overexpression pri odraslih bolnikih s potrjeno ali obstaja sum, dobro diferencirana gastro-enteropancreatic neuroendocrine tumorji (gep-net) za lokalizaciji primarnih tumorjev in njihove zasevki.